This bill establishes new provisions in Florida law regarding health insurance coverage for CAR T-cell therapies, which are advanced cancer treatments utilizing genetically modified T-cells. It creates three new sections in the Florida Statutes: 627.64198, 627.6614, and 641.3133, each addressing coverage for CAR T-cell therapies under individual health insurance policies, group health insurance policies, and health maintenance contracts, respectively. The bill defines key terms related to CAR T-cell therapy and mandates that, starting January 1, 2026, these insurance policies cannot refuse to contract with in-network health care facilities for the administration of CAR T-cell therapies or deny coverage for such treatments if the facilities are part of their provider networks.

The legislation aims to ensure that patients have access to necessary CAR T-cell therapies without facing barriers from their health insurance providers. It specifies that health insurance policies must cover the administration of CAR T cells and any related medications or procedures, provided they comply with FDA guidelines and the health care facility is included in the insurance policy's network for other services. The bill is set to take effect on January 1, 2026.